<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00054145</url>
  </required_header>
  <id_info>
    <org_study_id>PMH-PHL-014</org_study_id>
    <secondary_id>CDR0000269901</secondary_id>
    <secondary_id>NCI-5982</secondary_id>
    <nct_id>NCT00054145</nct_id>
  </id_info>
  <brief_title>Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer</brief_title>
  <official_title>A Phase 2 Study Of Perifosine In Metastatic Or Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of perifosine in treating patients who&#xD;
      have recurrent, refractory, locally advanced, or metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the objective tumor response rate in patients with recurrent or refractory,&#xD;
           locally advanced or metastatic breast cancer treated with perifosine.&#xD;
&#xD;
        -  Determine the toxicity of this drug in these patients.&#xD;
&#xD;
        -  Determine the stable disease rate, time to disease progression, objective response&#xD;
           duration, and duration of stable disease in patients treated with this drug.&#xD;
&#xD;
        -  Correlate potential endpoints, including phosphorylated ERK, PKB, and SAPK,&#xD;
           phosphorylated PKC alpha, beta, and gamma isoforms, p21 ^WAF1; and activated capase-3 in&#xD;
           tumor biopsies, with clinical outcome in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study.&#xD;
&#xD;
      Patients receive a loading dose of oral perifosine on days 1 and 2 and once daily on days&#xD;
      3-21 during course 1. Patients receive oral perifosine once daily on days 1-21 in each&#xD;
      subsequent course. Courses repeat every 28 days in the absence of disease progression or&#xD;
      unacceptable toxicity. Patients achieving a complete response (CR) may receive 2 additional&#xD;
      courses beyond the CR.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 18-35 patients will be accrued for this study within 6-12&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>perifosine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed breast cancer&#xD;
&#xD;
               -  Recurrent or refractory, locally advanced or metastatic disease&#xD;
&#xD;
          -  At least 1 unidimensionally measurable lesion&#xD;
&#xD;
               -  At least 20 mm by conventional techniques OR 10 mm by spiral CT scan&#xD;
&#xD;
               -  Previously irradiated lesions are not considered measurable unless they have&#xD;
                  demonstrated progression before study entry&#xD;
&#xD;
               -  No measurable disease limited to bone lesions&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  No history of hemolytic disorder&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.25 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST/ALT no greater than 2.5 times ULN (5 times ULN if liver metastases present)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No evidence of cardiac dysfunction&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No history of biliary flow obstruction&#xD;
&#xD;
          -  No abnormalities of the gastrointestinal tract that would preclude study drug&#xD;
             absorption&#xD;
&#xD;
          -  No active peptic ulcer disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No poorly controlled diabetes mellitus&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  No prior allergic reactions to compounds of similar chemical or biological composition&#xD;
             to perifosine&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No more than 2 prior lines of chemotherapy for advanced disease, excluding adjuvant&#xD;
             chemotherapy&#xD;
&#xD;
          -  Prior adjuvant chemotherapy allowed&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 4 weeks since prior endocrine therapy&#xD;
&#xD;
               -  Multiple lines of endocrine therapy for advanced disease allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
               -  Prior radiotherapy for metastatic disease allowed&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  No prior major gastric surgery&#xD;
&#xD;
          -  Prior surgery, including for metastatic disease, allowed&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other concurrent anticancer or investigational agents&#xD;
&#xD;
          -  No concurrent antiretroviral therapy in HIV-positive patients&#xD;
&#xD;
          -  Concurrent bisphosphonates allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natasha Leighl, MD, FRCPC</last_name>
    <role>Study Chair</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Margaret and Charles Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Ontario-London Regional Cancer Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Regional Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Leighl NB, Dent S, Clemons M, Vandenberg TA, Tozer R, Warr DG, Crump RM, Hedley D, Pond GR, Dancey JE, Moore MJ. A Phase 2 study of perifosine in advanced or metastatic breast cancer. Breast Cancer Res Treat. 2008 Mar;108(1):87-92. Epub 2007 Apr 26.</citation>
    <PMID>17458693</PMID>
  </results_reference>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>February 5, 2003</study_first_submitted>
  <study_first_submitted_qc>February 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2003</study_first_posted>
  <last_update_submitted>July 22, 2015</last_update_submitted>
  <last_update_submitted_qc>July 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>male breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

